drugset / Trial / NCT00197158

Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response

NCT00197158

Phase 4 Completed 280 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindPrevention

Summary

GSK Biologicals' currently licensed multidose hepatitis B vaccine will be compared to the currently licensed monodose hepatitis B vaccine in a population with well documented hepatitis B immunological response to the vaccine (Belgium).

Timeline

Start
2005-03
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix-B Vaccine